Subject(s)
Kidney Transplantation , Lymphatic System/pathology , Animals , Dogs , Female , Lymph/physiology , Male , Time Factors , Transplantation, AutologousSubject(s)
Graft Rejection , Kidney Transplantation , Acute Disease , Cadaver , Humans , Kidney/immunology , Kidney/pathology , Male , Middle Aged , Transplantation Immunology , Transplantation, HomologousABSTRACT
Intravesical instillations of 10% dibunol liniment were used for the treatment of 132 patients with bladder tumors. An objective improvement was noted in 62.4%, including considerable lessening of the tumor size in 20% and its disappearance in 8.8% of patients. An efficacy of the treatment was considerably greater in bladder cancer in stages T1--T2 than in stages T3 and T4. The frequency of bladder cancer recurrence is found to be lowered following surgery associated with application of dibunol, also the manifest antiinflammatory activity of the drug is emphasized. No side effects relative to the toxic action of dibunol were observed. The use of dibunol seems to be rational in patients with bladder tumors of early stages, especially if associated with surgical therapy, and in tumor recurrences, and also with the symptomatic purposes in inoperable patients.
